Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 89c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 89c

Eagle Pharmaceuticals Reports Third Quarter 2020 Results

November 2, 2020 6:47 AM EST

-- Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share --

-- Granted Priority Review by U.S. Food and Drug Administration (FDA) for vasopressin; trial date set for January 11, 2021 --

-- Held positive Type C meeting with FDA on fulvestrant (EA-114); next step is to submit formal protocol for clinical study --

-- Promoted Brian Cahill as Eagles new Chief Financial Officer --

-- Added experienced pharmaceutical industry executives to... More